US 2022/0175921 A1 · ANTIBODIES AGAINST GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND USES THEREOF

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

AssigneeBristol-Myers Squibb Company

InventorsChangyu WANG, Nils LONBERG, Alan J. KORMAN, Mark J. SELBY, Mohan SRINIVASAN, Karla A. HENNING, Michelle Minhua HAN, Guodong CHEN, Richard Y. HUANG, Indrani CHAKRABORTY, Haichun HUANG, Susan Chien-Szu WONG, Huiming LI, Bryan C. BARNHART, Aaron P. YAMNIUK, Ming LEI, Liang SCHWEIZER, Sandra V. HATCHER, Arvind RAJPAL

Life of this patent

Estimating the term…

Abstract

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Claims20

Dependent claims

1-68. (canceled)

A method for inhibiting the growth of tumor cells in a subject, the method comprising administering to the subject an antibody that binds to human glucocorticoid-inducible TNF receptor (GITR) and comprises a heavy chain constant region comprising (1) an amino acid sequence selected from the group consisting of SEQ ID NOs:

223-226, 283-290, 383-446 and 480-543 or (2) a heavy chain constant region that differs therefrom in at most 5 amino acids or is at least 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence of SEQ ID NOs:
223-226, 283-290, 383-446 and 480-543, wherein the amino acid modification(s) are not at the specific amino acid(s) in SEQ ID NOs:
223-226, 283-290, 383-446 and 480-543 that are not present in the naturally-occurring human heavy chain constant regions.

A method of treating cancer, the method comprising administering to a subject in need thereof a therapeutically effective amount of an antibody that binds to human glucocorticoid-inducible TNF receptor (GITR) and comprises a heavy chain constant region comprising (1) an amino acid sequence selected from the group consisting of SEQ ID NOs:

223-226, 283-290, 383-446 and 480-543 or (2) a heavy chain constant region that differs therefrom in at most 5 amino acids or is at least 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence of SEQ ID NOs:
223-226, 283-290, 383-446 and 480-543, wherein the amino acid modification(s) are not at the specific amino acid(s) in SEQ ID NOs:
223-226, 283-290, 383-446 and 480-543 that are not present in the naturally-occurring human heavy chain constant regions.

Dependencies are inferred from the claim text.